scholarly journals Prophylactic Bilateral Salpingo-oophorectomy in BRCA2 Mutation with Incidental Finding of Serous Tubal Intraepithelial Carcinoma (STIC) and Subsequent Diagnosis of Primary Peritoneal Carcinoma (PPC): A Case Report and Review of Current Literature

Cureus ◽  
2020 ◽  
Author(s):  
Konstantinos Palaiologos ◽  
Ahmed Ellaboudy ◽  
Mohammed Abdullah ◽  
Seema Karan ◽  
Arabinda Saha
Keyword(s):  
Case Report ◽  
Current Literature ◽  
Incidental Finding ◽  
Brca2 Mutation ◽  
Peritoneal Carcinoma ◽  
Serous Tubal Intraepithelial Carcinoma ◽  
Primary Peritoneal Carcinoma ◽  
Intraepithelial Carcinoma

scholarly journals Primary peritoneal carcinoma metastasizing to breast: a single case report and literature review from clinic to biology

2016 ◽  
Vol 13 (3) ◽  
pp. 389-395 ◽  
Author(s):  
Ji-Yuan Sun ◽  
Ji-Yuan Sun ◽  
Wondwossen Gebre ◽  
Yi-Min Dong ◽  
Xiao Shaun ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Single Case ◽  
Peritoneal Carcinoma ◽  
Primary Peritoneal Carcinoma ◽  
Single Case Report

scholarly journals Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma

2013 ◽  
Vol 2013 ◽  
pp. 1-3
Author(s):  
Mustafa M. Mohammad ◽  
Kostas N. Syrigos ◽  
M. Wasif Saif
Keyword(s):  
Case Report ◽  
Skin Rash ◽  
Drug Response ◽  
Single Agent ◽  
Surrogate Marker ◽  
Positive Outcome ◽  
Response To Therapy ◽  
Peritoneal Carcinoma ◽  
Primary Peritoneal Carcinoma

Vinorelbine (Navelbine, VRL) is commonly used for platinum-resistant ovarian cancer and has been shown to be effective in patients with recurrent primary peritoneal carcinoma. Of VRL’s major side effects, skin rash is uncommon, and, if it does occur, it is usually localized to site of injection. In this case report, a 71-year-old Hispanic female with primary peritoneal carcinoma received single agent VRL as fourth-line regimen, which she tolerated very well except for a skin rash related to VRL. The rash continued to progress throughout 6 cycles of VRL, and follow-up CT/PET scan demonstrated complete metabolic and radiological responses. We, therefore, believe that this rash was linked to VRL administration and correlated with response to therapy. Rash has been recognized as a useful surrogate marker with targeted agents such as cetuximab and erlotinib; to the best of our knowledge, this case report describes the first patient with a possible drug rash and its association with a positive outcome. This case report incites interest in further investigation of similar cases to support this observation, since there is a lack of reports of skin rash with VRL therapy.

Extraovarian primary peritoneal carcinoma presenting as adenocarcinoma in endometrial cytology: A case report

2010 ◽  
Vol 49 (6) ◽  
pp. 412-418
Author(s):  
Akemi NOZAWA ◽  
Hiroto UEDA ◽  
Asako KANAI ◽  
Yuichi SIMOE ◽  
Yoshihide IKAWA ◽  
...  
Keyword(s):  
Case Report ◽  
Peritoneal Carcinoma ◽  
Primary Peritoneal Carcinoma ◽  
Endometrial Cytology
Sign in / Sign up

Export Citation Format

Share Document